| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 912 | 2016 |
| Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin MG Oser, MJ Niederst, LV Sequist, JA Engelman The Lancet Oncology 16 (4), e165-e172, 2015 | 833 | 2015 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 789 | 2014 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 581 | 2015 |
| The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies MJ Niederst, H Hu, HE Mulvey, EL Lockerman, AR Garcia, Z Piotrowska, ... Clinical Cancer Research 21 (17), 3924-3933, 2015 | 554 | 2015 |
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee, JW Neal, ... Cancer discovery 5 (7), 713-722, 2015 | 501 | 2015 |
| Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer MJ Niederst, JA Engelman Science signaling 6 (294), re6-re6, 2013 | 270 | 2013 |
| Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? PA Bunn Jr, JD Minna, A Augustyn, AF Gazdar, Y Ouadah, MA Krasnow, ... Journal of Thoracic Oncology 11 (4), 453-474, 2016 | 202 | 2016 |
| Primary patient-derived cancer cells and their potential for personalized cancer patient care DP Kodack, AF Farago, A Dastur, MA Held, L Dardaei, L Friboulet, ... Cell reports 21 (11), 3298-3309, 2017 | 199 | 2017 |
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia, D Timonina, E Labrot, ... Oncogene 38 (37), 6399-6413, 2019 | 178 | 2019 |
| KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer EB Krall, B Wang, DM Munoz, N Ilic, S Raghavan, MJ Niederst, K Yu, ... Elife 6, e18970, 2017 | 151 | 2017 |
| Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms H Hu, Z Piotrowska, PJ Hare, H Chen, HE Mulvey, A Mayfield, S Noeen, ... Cancer Cell 39 (11), 1531-1547. e10, 2021 | 127 | 2021 |
| EGF816 exerts anticancer effects in non–small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor Y Jia, J Juarez, J Li, M Manuia, MJ Niederst, C Tompkins, N Timple, ... Cancer research 76 (6), 1591-1602, 2016 | 126 | 2016 |
| Suppression of survival signalling pathways by the phosphatase PHLPP AK O’Neill, MJ Niederst, AC Newton The FEBS journal 280 (2), 572-583, 2013 | 107 | 2013 |
| Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification JF Gainor, MJ Niederst, JK Lennerz, I Dagogo-Jack, S Stevens, AT Shaw, ... Journal of Thoracic Oncology 11 (7), e83-e85, 2016 | 88 | 2016 |
| Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM KA Song, MJ Niederst, TL Lochmann, AN Hata, H Kitai, J Ham, KV Floros, ... Clinical Cancer Research 24 (1), 197-208, 2018 | 84 | 2018 |
| Osimertinib responses after disease progression in patients who had been receiving rociletinib LV Sequist, Z Piotrowska, MJ Niederst, RS Heist, S Digumarthy, AT Shaw, ... JAMA oncology 2 (4), 541-543, 2016 | 65 | 2016 |
| Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine … NA Warfel, M Niederst, MW Stevens, PM Brennan, MC Frame, AC Newton Journal of Biological Chemistry 286 (22), 19777-19788, 2011 | 48 | 2011 |
| Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C J Brognard, M Niederst, G Reyes, N Warfel, AC Newton Journal of biological chemistry 284 (22), 15215-15223, 2009 | 46 | 2009 |
| Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2 NA Warfel, M Niederst, AC Newton Journal of Biological Chemistry 286 (45), 39122-39129, 2011 | 39 | 2011 |
